BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...Diego, Calif.) hired Kevin Finney as president, COO and a director. Finney was COO at Zavante Therapeutics Inc....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Vernalis plc (LSE:VER) 8/9/18 $43 NA $43 Nabriva Therapeutics plc (NASDAQ:NBRV) Zavante Therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Nabriva acquires Zavante

...Nabriva Therapeutics plc (NASDAQ:NBRV) acquired Zavante Therapeutics Inc. (San Diego, Calif.) for 8.2 million Nabriva shares, or $27.1...
...company’s close of $3.30 on July 24, before the acquisition was announced after market close. Zavante...
...Zavante Therapeutics Inc., San Diego, Calif. Nabriva Therapeutics plc (NASDAQ:NBRV), Dublin, Ireland Business: Infectious Jaime De Leon Zolyd, fosfomycin (ZTI-01) Zavante Therapeutics Inc. Nabriva...
BioCentury | Apr 7, 2017
Clinical News

Zolyd: Ph II/III ZEUS data

...eligible for 5 additional years of exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act. Zavante Therapeutics Inc....
...and microbiologic eradication rates and pharmacokinetics Status: Phase II/III data Milestone: Submit NDA (early 2018) Meghan Sullivan fosfomycin ZTI-01 Zavante Therapeutics Inc. Zolyd...
BioCentury | Apr 6, 2017
Clinical News

Zavante's Zolyd meets in pivotal cUTI study

...at the test-of-cure (TOC) visit on day 19, meeting ZEUS's primary endpoint (64.7% vs. 54.5%). Zavante...
...receive thrice-daily 6 g IV Zolyd or 4.5 g piperacillin/tazobactam for seven to 14 days. Zavante...
...designations from FDA to treat cUTI (see BioCentury, April 4, 2016) . In March 2016, Zavante...
BioCentury | Jan 24, 2017
Clinical News

Fosfomycin: Ph II/III ZEUS ongoing

...comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days. Zavante...
...with response of microbiologic eradication and pharmacokinetics Status: Phase II/III ongoing Milestone: Submit NDA (2H17) Julian Zhu fosfomycin ZTI-01 Zavante Therapeutics Inc....
BioCentury | Apr 25, 2016
Clinical News

Fosfomycin: Pivotal trial started

...to compare IV ZTI-01 vs. piperacillin/tazobactam in 460 hospitalized adults with cUTIs, including acute pyelonephritis. Zavante Therapeutics Inc....
BioCentury | Apr 5, 2016
Financial News

Antibacterial play Entasis raises $50M series B

...Entasis' board. Last month, Frazier invested in series A rounds for two other antibiotics companies: Zavante Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

Frazier's GAIN

...series A rounds for antibiotics companies in the span of a week. On March 30, Zavante Therapeutics Inc....
...Act, which Congress passed in 2012, was critical in persuading investors to pursue the deals. Zavante...
...right down the fairway of what Congress hoped to achieve with the GAIN Act," added Zavante...
BioCentury | Apr 4, 2016
Financial News

Zavante completes venture financing

Zavante Therapeutics Inc. , San Diego, Calif. Business: Infectious Date completed: 2016-03-30 Type: Venture financing Raised: $45 million Investors: Frazier Healthcare; Longitude Capital Management; Aisling Capital Note: The offering includes the conversion of $10 million in...
Items per page:
1 - 10 of 11
BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...Diego, Calif.) hired Kevin Finney as president, COO and a director. Finney was COO at Zavante Therapeutics Inc....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Vernalis plc (LSE:VER) 8/9/18 $43 NA $43 Nabriva Therapeutics plc (NASDAQ:NBRV) Zavante Therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Nabriva acquires Zavante

...Nabriva Therapeutics plc (NASDAQ:NBRV) acquired Zavante Therapeutics Inc. (San Diego, Calif.) for 8.2 million Nabriva shares, or $27.1...
...company’s close of $3.30 on July 24, before the acquisition was announced after market close. Zavante...
...Zavante Therapeutics Inc., San Diego, Calif. Nabriva Therapeutics plc (NASDAQ:NBRV), Dublin, Ireland Business: Infectious Jaime De Leon Zolyd, fosfomycin (ZTI-01) Zavante Therapeutics Inc. Nabriva...
BioCentury | Apr 7, 2017
Clinical News

Zolyd: Ph II/III ZEUS data

...eligible for 5 additional years of exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act. Zavante Therapeutics Inc....
...and microbiologic eradication rates and pharmacokinetics Status: Phase II/III data Milestone: Submit NDA (early 2018) Meghan Sullivan fosfomycin ZTI-01 Zavante Therapeutics Inc. Zolyd...
BioCentury | Apr 6, 2017
Clinical News

Zavante's Zolyd meets in pivotal cUTI study

...at the test-of-cure (TOC) visit on day 19, meeting ZEUS's primary endpoint (64.7% vs. 54.5%). Zavante...
...receive thrice-daily 6 g IV Zolyd or 4.5 g piperacillin/tazobactam for seven to 14 days. Zavante...
...designations from FDA to treat cUTI (see BioCentury, April 4, 2016) . In March 2016, Zavante...
BioCentury | Jan 24, 2017
Clinical News

Fosfomycin: Ph II/III ZEUS ongoing

...comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days. Zavante...
...with response of microbiologic eradication and pharmacokinetics Status: Phase II/III ongoing Milestone: Submit NDA (2H17) Julian Zhu fosfomycin ZTI-01 Zavante Therapeutics Inc....
BioCentury | Apr 25, 2016
Clinical News

Fosfomycin: Pivotal trial started

...to compare IV ZTI-01 vs. piperacillin/tazobactam in 460 hospitalized adults with cUTIs, including acute pyelonephritis. Zavante Therapeutics Inc....
BioCentury | Apr 5, 2016
Financial News

Antibacterial play Entasis raises $50M series B

...Entasis' board. Last month, Frazier invested in series A rounds for two other antibiotics companies: Zavante Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

Frazier's GAIN

...series A rounds for antibiotics companies in the span of a week. On March 30, Zavante Therapeutics Inc....
...Act, which Congress passed in 2012, was critical in persuading investors to pursue the deals. Zavante...
...right down the fairway of what Congress hoped to achieve with the GAIN Act," added Zavante...
BioCentury | Apr 4, 2016
Financial News

Zavante completes venture financing

Zavante Therapeutics Inc. , San Diego, Calif. Business: Infectious Date completed: 2016-03-30 Type: Venture financing Raised: $45 million Investors: Frazier Healthcare; Longitude Capital Management; Aisling Capital Note: The offering includes the conversion of $10 million in...
Items per page:
1 - 10 of 11